Pleural mesothelioma WT1 vaccine is renamed “galinpepimut-S”

8 Apr 2016 by under Research/Treatment

research test tubes 100x100 Pleural mesothelioma WT1 vaccine is renamed galinpepimut SA clinical-stage immunotherapy vaccine to be used for the of malignant pleural mesothelioma, as well as a wide range of hematologic cancers and solid tumors, has been dubbed “galinpepimut-S” by the United States Adopted Named Council of the American Medical Association.

Mesothelioma is a rare form of cancer that can remain latent in those exposed for 30 to 40 years, eventually spreading to the smooth lining of the chest, lungs, heart, or abdomen. The layer of tissue surrounding these organs is made up of mesothelial cells, thus why the disease is called mesothelioma. There are three types of mesothelioma that have been identified within the U.S. —pleural, peritoneal, and pericardial. The most common form and the one addressed by the vaccine, pleural mesothelioma, affects the lining of the lungs. In the U.S. alone, there are about 2,500 cases of pleural mesothelioma identified annually.

The WT1 vaccine was originally developed by the Memorial Sloan Kettering Cancer Center, but is now licensed to the Life Sciences Group. Its purpose is to stimulate certain immune cells, including cytotoxic T-cells, to react against the WT1 antigen not commonly found in healthy adult cells, but expressed in large quantities for those suffering with cancer. The National Cancer Institute (NCI) ranked the WT1 antigen as the top target for cancer immunotherapy.

“We expect 2016 to be an exceptional year for the progress of our advanced-stage WT1 program,” Miltiadis Sougioultzoglou, MD, vice chairman and executive vice president of SELLAS, said in a recent press release regarding the vaccine. “Over the course of the next three quarters, we anticipate announcing the start of two pivotal studies, in MPM [malignant pleural mesothelioma] and AML, as well as multiple Phase 2 studies in additional solid tumors and hematological malignancies.”

The vaccine is administered with an adjuvant and an immune modulator to help the immune system respond to its effects more easily. It is hoped that the vaccine will be able to assist in other treatments for serious health conditions, such as acute myeloid leukemia (AML), multiple myeloma, and ovarian cancer.

Source: Mesothelioma Research News


Comments are closed.